Cancer Family
Carcinoma
CI-CAN-00000114Explore in graph →
7,363 active trials118 approved drugs1,149 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000114Explore in graph →
Clinical trials
25,720 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3,404)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05908734 | A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer(PolyDamas) | active not recruiting | Phase 1 / Phase 2 | 71 | Janssen Research & Development, LLCINDUSTRY | 9 | Sep 25, 2026 | clinicaltrials |
| NCT05922930 | Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer | active not recruiting | Phase 1 / Phase 2 | 51 | M.D. Anderson Cancer Center |
| 1 |
| Sep 25, 2026 |
| clinicaltrials |
| NCT06116786 | A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer | active not recruiting | Phase 1 | 67 | Johnson & Johnson Enterprise Innovation Inc.INDUSTRY | 4 | Sep 25, 2026 | clinicaltrials |
| NCT06120140 | Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib(COCOON) | active not recruiting | Phase 2 | 305 | Janssen Research & Development, LLCINDUSTRY | 11 | Sep 25, 2026 | clinicaltrials |
| NCT06211764 | A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)(SunRISe-5) | active not recruiting | Phase 3 | 272 | Janssen Research & Development, LLCINDUSTRY | 14 | Sep 25, 2026 | clinicaltrials |
| NCT06369610 | Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer | active not recruiting | Phase 2 | 110 | Mayo ClinicOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06496178 | A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2) | active not recruiting | Phase 3 | 621 | Merus B.V.INDUSTRY | 24 | Sep 25, 2026 | clinicaltrials |
| NCT06525220 | A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) | active not recruiting | Phase 3 | 699 | Merus B.V.INDUSTRY | 28 | Sep 25, 2026 | clinicaltrials |
| NCT06579196 | Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1 | active not recruiting | Phase 1 / Phase 2 | 45 | University of NebraskaOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06910670 | Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid | active not recruiting | N/A | 197 | Washington University School of MedicineOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07183189 | A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC | active not recruiting | Phase 3 | 582 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT02293954 | Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer | active not recruiting | N/A | 20 | City of Hope Medical CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT03085043 | Magnetic Resonance Whole Body Diffusion-Weighted Imaging in Finding Bone or Lymph Node Metastasis in Participants With High-Risk Prostate Cancer | active not recruiting | N/A | 98 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04624204 | Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) | active not recruiting | Phase 3 | 672 | Merck Sharp & Dohme LLCINDUSTRY | 25 | Sep 24, 2026 | clinicaltrials |
| NCT05152147 | A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers(HERIZON-GEA-01) | active not recruiting | Phase 3 | 920 | Jazz PharmaceuticalsINDUSTRY | 33 | Sep 24, 2026 | clinicaltrials |
| NCT05215340 | Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations(TROPION-Lung08) | active not recruiting | Phase 3 | 740 | Daiichi SankyoINDUSTRY | 28 | Sep 24, 2026 | clinicaltrials |
| NCT05241860 | Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)(A-DREAM) | active not recruiting | Phase 2 | 79 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05717998 | Imaging and Blood-Based Biomarkers for the Evaluation of Early Signs of Myocardial Injury After Thoracic Radiation Therapy | active not recruiting | — | 28 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06447662 | A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. | active not recruiting | Phase 1 | 64 | PfizerINDUSTRY | 2 | Sep 24, 2026 | clinicaltrials |
| NCT06462222 | Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 45 | Guangzhou Medical UniversityOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07757906 | Clinical Application of an AI-based Dissection Trajectory Prediction System (ADTPS) in Endoscopic Submucosal Dissection | active not recruiting | N/A | 220 | Qilu Hospital of Shandong UniversityOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT02194738 | Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) | active not recruiting | N/A | 7,458 | National Cancer Institute (NCI)NIH | 3 | Sep 23, 2026 | clinicaltrials |
| NCT03381274 | Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study | active not recruiting | Phase 1 / Phase 2 | 43 | MedImmune LLCINDUSTRY | 3 | Sep 23, 2026 | clinicaltrials |
| NCT04044859 | ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) | active not recruiting | Phase 1 | 120 | USWM CT, LLCINDUSTRY | 3 | Sep 23, 2026 | clinicaltrials |
| NCT04062708 | CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 38 | Alliance Foundation Trials, LLC.OTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT04715958 | SHAPE Neoadjuvant Chemotherapy Response | active not recruiting | Phase 2 / Phase 3 | 122 | Kibo NamOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT04989504 | Testing the Application of Mepitel Film During Radiation Therapy to Reduce Radiation Related Redness and Peeling in Breast Cancer Patients Following Mastectomy | active not recruiting | Phase 3 | 216 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT05144997 | Lorlatinib Continuation Study | active not recruiting | Phase 4 | 76 | PfizerINDUSTRY | 8 | Sep 23, 2026 | clinicaltrials |
| NCT05814549 | A Study Using Human Papillomavirus (HPV) DNA Testing to Detect HPV-Related Oropharyngeal Cancer (OPC) | active not recruiting | — | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06253520 | Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer | active not recruiting | Phase 1 | 210 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06337552 | High-Fermented Food Intervention Among Locally Advanced Rectal Cancer Patients (The FEED Trial) | active not recruiting | N/A | 39 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06564844 | A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features(TROPION-Lung12) | active not recruiting | Phase 3 | 25 | AstraZenecaINDUSTRY | 10 | Sep 23, 2026 | clinicaltrials |
| NCT06843655 | Radiological Markers in Locally Advanced Rectal Cancer(LARC) | active not recruiting | — | 179 | IRCCS San RaffaeleOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT01660984 | Natural History Study of Children and Adults With Medullary Thyroid Cancer | active not recruiting | — | 105 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT02314169 | Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer | active not recruiting | Phase 2 | 143 | National Cancer Institute (NCI)NIH | 2 | Sep 22, 2026 | clinicaltrials |
| NCT03965689 | Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy | active not recruiting | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT04079712 | Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors | active not recruiting | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 2 | Sep 22, 2026 | clinicaltrials |
| NCT04810078 | A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread(CheckMate-67T) | active not recruiting | Phase 3 | 681 | Bristol-Myers SquibbINDUSTRY | 17 | Sep 22, 2026 | clinicaltrials |
| NCT04963153 | Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy | active not recruiting | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 2 | Sep 22, 2026 | clinicaltrials |
| NCT05009836 | Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC(SANOVO) | active not recruiting | Phase 3 | 412 | HutchmedINDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05276973 | Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer | active not recruiting | Phase 1 | 25 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05446298 | ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer(PRESERVE-004) | active not recruiting | Phase 2 | 58 | OncoC4, Inc.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05913388 | GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 2 | 12 | Providence Health & ServicesOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05977907 | Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).(KIEO) | active not recruiting | Phase 2 | 30 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06109272 | A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)(LIVIGNO-2) | active not recruiting | Phase 2 / Phase 3 | 89 | AbbVieINDUSTRY | 6 | Sep 22, 2026 | clinicaltrials |
| NCT06140836 | A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) | active not recruiting | Phase 3 | 190 | Bristol-Myers SquibbINDUSTRY | 21 | Sep 22, 2026 | clinicaltrials |
| NCT06151574 | Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | active not recruiting | Phase 3 | 428 | Boehringer IngelheimINDUSTRY | 26 | Sep 22, 2026 | clinicaltrials |
| NCT06894511 | An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC(PSMAndARPI) | active not recruiting | Phase 2 | 7 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT02968732 | Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladder | active not recruiting | N/A | 65 | Fox Chase Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 25, 2026source: clinicaltrials